Compugen
在场
Compugen 是一家在股票代码 CGEN (IL) 下上市的公司。
高管
查看带有其 40 名主要高管的组织结构图
Compugen 搜索最多的简介
- Anat Cohen-Dayag, Director, Employee Representative
- Mathias Hukkelhoven, Director
- Eran Perry, Director
高管在Compugen变化
- David SilbermanDavid Silberman 将于20248月15作为 Chief Financial Officer 加入公司 (新闻发布的2024五月16号).
- Alberto Sessa, Chief Financial Officer, 将于 20248月15 退休 (新闻发布的2024五月16号).
- Michelle Mahler 曾任 Vice President of Clinical Development, 将于 20243月1 升职为 Chief Medical Officer (新闻发布的2024二月16号).
创建提醒
跟踪 Compugen 的高管变动
生物技术
Compugen 拥有 2,292 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Lycia Therapeutics 刚刚宣布为 107 筹款数百万美元。 (公布2024五月15号).
- Attovia Therapeutics 刚刚宣布为 150 筹款数百万美元。 (公布2024五月14号).
- Bruker has announced the acquisition of NanoString Technologies (公布2024五月13号).
生物技术 行业的其他推荐联系人
消息
Compugen 的最新新闻稿
- Compugen Appoints David Silberman as Chief Financial Officer
- Compugen Appoints David Silberman as Chief Financial Officer
- Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
- Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
- Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
- Compugen to Participate in Two Upcoming Investor Conferences
- Compugen Reports Fourth Quarter and Full Year 2023 Results
- Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
- Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
- Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
- View more press releases Close
关于 Compugen 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Anat Cohen-Dayag 
